| Literature DB >> 27699181 |
Simone A Joosten1, Lucy C Sullivan2, Tom H M Ottenhoff1.
Abstract
Human HLA-E can, in addition to self-antigens, also present pathogen-derived sequences, which elicit specific T-cell responses. T-cells recognize their antigen presented by HLA-E highly specifically and have unique functional and phenotypical properties. Pathogen specific HLA-E restricted CD8+ T-cells are an interesting new player in the field of immunology. Future work should address their exact roles and relative contributions in the immune response against infectious diseases.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27699181 PMCID: PMC5028793 DOI: 10.1155/2016/2695396
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Figure 1HLA-E serves a dual role in the immune system. HLA-E presents antigens, including pathogen-derived antigens on the cell surface of most cells. NK cells, as part of the innate immune system, will sense the presence of HLA-E presenting self or pathogen-derived peptides and thereby receive inhibitory signals from the CD94/NKG2A complex such that NK mediated lysis will be inhibited. In addition, CD8+ T-cells may specifically recognize foreign peptide presented by HLA-E and become activated through their T-cell receptor, resulting in T-cell activation, expansion, and memory formation in the adaptive immune system.
Antigen types/characteristics presented in HLA-E and recognized by T-cells.
| Sequence | Origin | Description of antigen | Patients/donors | Recognition by T-cells | Reference |
|---|---|---|---|---|---|
| ? |
| Glycopeptide from Mpt32 | T-cell clones derived from latently infected individuals | IFN | [ |
|
| |||||
| SLELGDSAL | Human | TCR V | Healthy donors, | Target cell lysis | [ |
| LLLGPGSGL | TCR V | ||||
|
| |||||
| SQAPLPCVL |
| BZLF1 | T-cells from healthy donor; MS patients | T-cell proliferation, target cell lysis, TM staining | [ |
|
| |||||
| VTAPRTVLL | Human | HLA-B15 | T-cell lines from healthy donors | T-cell proliferation, target cell lysis | [ |
| VMAPRALLL | Human | HLA-Cw7 | |||
| VMAPRTLFL | Human | HLA-G1 | |||
|
| |||||
| VMAPRTLIL |
| UL40 | T-cell lines from healthy donors; lung transplant recipients | NK-CTL proliferation, target cell lysis, TM staining | [ |
| VMAPRTLVL | |||||
| VMAPRTLLL | |||||
|
| |||||
| GMQFDRGYL |
|
| Healthy volunteers vaccinated with | Target cell lysis | [ |
| AMLQDIATL | |||||
| KMLRGVNVL | |||||
| VEGEALATL | |||||
| AAVEELKAL | |||||
| AVAKAGKPL | |||||
| KLQERVAKL | |||||
|
| |||||
| YLLPRRGPRL |
| Peptide HCV core aa 35–44 | Chronic hepatitis C patients | IFN | [ |
|
| |||||
| 69 peptides |
| Multiple proteins expressed by Mtb | Latently infected individuals, BCG vaccinated newborns | CD8+ T-cell proliferation | [ |
|
| |||||
| QMRPVSRVL | Human | Hsp60sp | Healthy donors, patients with type I diabetes | T-cell proliferation, target cell lysis | [ |
|
| |||||
| ? |
| ? | Healthy volunteers vaccinated with | Cytokine producing T-cells | [ |
|
| |||||
| RMPPLGHEL |
| Rv2997, alanine rich dehydrogenase | T-cell clones derived from latently infected individuals | CD137 expression, ZAP70 phosphorylation; CD8+ T-cell proliferation, TNF | [ |
| VLRPGGHFL |
| Rv1523, methyltransferase | |||
|
| |||||
| VMTTVLATL |
| Rv1734c, conserved hypothetical protein | Patients with pulmonary TB | CD8+ T-cell proliferation, TNF | [ |
| RLPAKAPLL |
| Rv1484, NADH-dependent enoyl reductase InhA | |||
| VMATRRNVL |
| Rv1518, unknown, possibly glycosyl transferase | |||
| VLRPGGHFL |
| Rv1523, methyltransferase | |||
|
| |||||
| ? |
| ? | Healthy donors challenged with | Cytokine production | [ |
D. Lewinsohn, personal communication, manuscript in preparation.
Figure 2Crystal structure of the HLA-E/KK50.4 TCR complex [12]. (a) Overview of the HLA-E/KK50.4 TCR structure showing two orthogonal views. The HLA-E heavy chain is shown in grey ribbons, the UL40 peptide in pink sticks, and β2m in blue ribbons. The KK50.4 alpha and beta chains are shown as orange and green ribbons, respectively. (b) The convergence of all 3 CDR β loops onto P8 Ile of the peptide bound to HLA-E. The HLA-E heavy chain is grey, peptide is pink, CDR1β is yellow, CDR2β is green, and CDR3β is shown in red.
T-cell properties of MHC class Ib restricted T-cells; phenotype, cytokine production, transcription factors, cytolytic molecules.
| Antigen | T-cell phenotype | Cytokines | Transcr. factors | Function | Reference | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD3 | CD8 | TCR | CD25 | LAG3 | CD39 | CTLA4 | CD45RA | CD45RO | CCR7 | CD27 | CD28 | CD56 | CD57 | CD62L | CD94 | Perforin | Granzyme A | Granzyme B | Granulysin | CD107a | TRAIL | TCR V | TCR V | IFN | TNF | IL-2 | IL-4 | IL-5 | IL-10 | IL-13 | IL-17 | TGF- | MIP-1 | T-bet | GATA3 | RORC | FOXP3 | EOMES | Spec. target lysis | Path. killing | T-cell suppr. | TM binding | |||
| Self | VMAPRTLVL | + | + | + | [ | ||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Self | VTAPRTVLL | + | + | + | [ | ||||||||||||||||||||||||||||||||||||||||
| VMAPRTLVL | + | + | + | ||||||||||||||||||||||||||||||||||||||||||
| VMAPRTLIL | + | + | + | ||||||||||||||||||||||||||||||||||||||||||
| VMAPRALLL | + | + | + | ||||||||||||||||||||||||||||||||||||||||||
| VMAPRTLFL | + | + | + | ||||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Self | VMAPRTLIL, VMAPRTLLL | + | + | + | + | + | + | [ | |||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Self | QMRPVSRVL | + | + | + | + | + | [ | ||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Self | SLELGDSAL | + | + | [ | |||||||||||||||||||||||||||||||||||||||||
| LLLGPGSGL | + | + | |||||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| EBV | SQAPLPCVL | + | + | + | [ | ||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| EBV | SQAPLPCVL | + | + | + | + | + | + | [ | |||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| EBV | SQAPLPCVL | + | + | [ | |||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| CMV | VMAPRTLIL | + | + | − | + | + | [ | ||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| CMV | VMAPRTLIL | + | + | + | − | − | − | + | + | + | + | − | + | + | [ | ||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| CMV | VMAPRTLIL, VMAPRTLVL | + | + | + | [ | ||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| CMV | VMAPRTLLL | + | + | + | lo | hi | − | − | # | + | − | − | + | + | + | + | + | + | ? | + | [ | ||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| CMV | VMAPRTLIL | + | − | + | + | [ | |||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| HCV | YLLPRRGPRL | + | + | [ | |||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Salmonella | GMQFDRGYL | + | + | − | + | + | + | [ | |||||||||||||||||||||||||||||||||||||
| AMLQDIATL | + | + | − | + | + | + | |||||||||||||||||||||||||||||||||||||||
| KMLRGVNVL | + | + | − | + | + | + | |||||||||||||||||||||||||||||||||||||||
| VEGEALATL | + | + | − | + | + | + | |||||||||||||||||||||||||||||||||||||||
| AAVEELKAL | + | + | − | + | + | + | |||||||||||||||||||||||||||||||||||||||
| AVAKAGKPL | + | + | − | + | + | + | |||||||||||||||||||||||||||||||||||||||
| KLQERVAKL | + | + | − | + | + | + | |||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Salmonella | ? | + | + | # | − | + | + | + | # | + | + | [ | |||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Mtb | ? | + | + | [ | |||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Mtb | 69 peptides | + | + | + | + | + | − | # | + | + | # |
| − | + | + | [ | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Mtb | RMPPLGHEL | + | + | + | + | + | + | + | − | + | # | + | + | + | # | + | # | # | + | # | + | − | + | − | − | # | + | + | + | + | [ | ||||||||||||||
| VLRPGGHFL | + | + | + | + | + | + | + | − | + | # | + | + | + | # | + | # | # | + | # | + | − | + | − | − | # | + | + | + | + | ||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
| Mtb | VMTTVLATL | + | + | + | − | # | − | # | − | + | − | # | − | − | + | − | + | − | + | [ | |||||||||||||||||||||||||
| RLPAKAPLL | + | + | + | − | # | − | # | − | + | − | # | − | − | + | − | + | − | + | |||||||||||||||||||||||||||
| VMATRRNVL | + | + | + | − | # | − | # | − | + | − | # | − | − | + | − | + | − | + | |||||||||||||||||||||||||||
| RMPPLGHEL | + | + | + | − | # | − | # | − | + | − | # | − | − | + | − | + | − | + | |||||||||||||||||||||||||||
| VLRPGGHFL | + | + | + | − | # | − | # | − | + | − | # | − | − | + | − | + | − | + | |||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||
“+” = positive in most samples; “−” = hardly seen; #: observed in about half of the samples; ∗: membrane bound TGF-β, not secreted.